Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 126

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 126
---
, are properly maintained and are generally suitable for future needs. We regularly inspect and evaluate those facilities with regard to environmental, health, safety and security matters, quality compliance and capacity utilization. For more information about our property, plant and equipment, see Note D.3. to our consolidated financial statements, included at Item 18. of this annual report, and section “B.7. Production and Raw Materials” above. Our main production sites by volume are: • Le Trait (France), Frankfurt (Germany), Waterford (Ireland), Geel (Belgium) and Framingham (United States) for Specialty Care; • Aramon, Sisteron and Ambarès (France), Frankfurt (Germany), Csanyikvölgy (Hungary), Lüleburgaz (Turkey), Campinas (Brazil), Jurong (Singapore) and Hangzhou (China) for General Medicines products; • Marcy-l’Étoile and Val-de-Reuil (France), Toronto (Canada) and Swiftwater (United States) for vaccines; and • Compiègne and Lisieux (France), Cologne (Germany), Origgio (Italy), Chattanooga (United States) and Ocoyoacac (Mexico) for Opella products, now part of Sanofi’s discontinued operations (see “Item 5. Operating and Financial Review and Prospects — A.1.1. 2024 Overview”).

| 54 | SANOFIFORM 20-F2024 |

| PART I                             |
| ITEM 4. Information on the Company |

Research & Development sites In Pharmaceuticals, research and development activities are conducted at the following sites: • two operational sites in France: Montpellier and Vitry-sur-Seine/Alfortville; • two sites in the rest of Europe (Germany and Belgium), the larger of which is in Frankfurt (Germany); • three sites in the United States: Bridgewater, Cambridge and Framingham/Waltham ; and • three sites in China (Beijing, Shanghai and Chengdu). In Vaccines, research and development activities are conducted at the following sites : • Swiftwater, Cambridge and Orlando (United States); • Marcy-l’Étoile/Lyon (France); and • Toronto (Canada). D.3. Acquisitions, capital expenditures and divestitures The carrying amount of our property, plant and equipment at December 31, 2024 was € 10,091 million. During 2024 , we invested € 1,717 million (see Note